(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
about
Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancySolution Structure of a DNA Duplex Containing the Potent Anti-Poxvirus Agent CidofovirResistance of human cytomegalovirus to antiviral drugs.Clinical uses of cidofovir.Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replicationPrevention and treatment of cytomegalovirus infection in organ transplant recipients.Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsPotent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.In search of a selective antiviral chemotherapy.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.The use of antiviral drugs during the neonatal periodFirst pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay.Drug-induced uveitisIntravenous immunoglobulin as rescue therapy for BK virus nephropathy.Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions.Transporter-mediated drug-drug interactions.Peptide inhibitors against herpes simplex virus infections.Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.Cidofovir Activity against Poxvirus Infections.Quantitation of cytomegalovirus: methodologic aspects and clinical applications.Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingAntimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice.Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed PatientsBone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.Potent inhibition of hemangiosarcoma development in mice by cidofovir.Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience.Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis.Cidofovir in the treatment of cytomegalovirus (CMV) retinitis.Treatment of refractory BK virus-associated nephropathy with cidofovir.Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant.Cidofovir induces an increase in levels of low-risk and high-risk HPV E6.Intravitreal cidofovir injection for the management of chronic glaucoma in dogs.Cidofovir in the treatment of cytomegaloviral disease.
P2860
Q27005614-C22F9D0F-4D5B-4CAE-B477-FDBAB593F691Q27666791-7E96B5A6-3F1C-4C4C-8564-758A48A9F614Q33588911-5027E857-B35B-4670-863A-1BFA9A4A15BDQ33867391-E9A8464F-50A7-40ED-B057-D083EBD2E259Q34111115-412F037F-BDC3-4602-A1DF-B09E1872A1BEQ34294851-803AC409-05E5-4B71-AEA9-414C1C0BC164Q34510611-1FCB36BC-47BD-4FC8-A199-9F7974BA4249Q35126399-31071239-CFFE-43F6-9A21-AA77F872BFC4Q35375912-4BEA6264-424E-4F05-A491-E97E16CFB54DQ35558801-70C8E540-2AE3-464F-BB87-2A9FE3EE53C6Q35789702-B2C828D7-0C8B-4874-A5E1-AEB3D9254703Q35941261-A541EF2C-33C8-46E9-8FB3-B662399C606EQ36547227-2A397270-7483-439E-AD1B-F3371DB38488Q36797491-83BD461C-1B35-4C9A-9653-8B408AF2D580Q37281176-04AEF0DB-0527-4817-898D-04782E7850C5Q37492600-96763C1B-088E-440E-AE3C-E2850DB728D4Q37905033-EED58AD3-6321-4A3D-8B38-FDF768DB0210Q38079780-1F164635-931B-44CB-8F05-55A713CB9A77Q38530119-4FC75035-32A8-47B0-AF93-48BE07026839Q38614278-BD9E0E29-1866-4C63-BCB2-AE0459C2C027Q39468915-5DBED238-51DF-4C39-AA52-BCED537E8974Q39652845-9CB4B61E-3940-4EE3-8D02-82BAF2BE3677Q39782383-F6A96A2A-F32C-45FB-B571-D1189BFFCA2DQ40570063-10D062E5-DBBD-4C0F-AFE9-9CAD521AF9F9Q40706720-BC925BDA-535E-4DBB-9F74-9C9C6F903DF0Q40814289-9146ED19-A494-451C-849C-EC79AA077001Q42248036-6E4D1C50-8C4B-4915-902C-BFEC73BE97A7Q42692480-B83B2128-2EAC-4E5F-AE47-CD9F9CDD6E93Q43649096-3E545BB5-2BFA-41AC-B7DE-1DACB366364EQ44339748-6D611071-EADF-4ABE-9232-2804F041CF0EQ45405066-44F084D7-8A08-4710-A4DE-F261B9A53E36Q46089829-5F710378-C36D-4D1B-ADF1-30767B5F2148Q47999117-16368C1C-3772-4DAD-953C-A712E8B76435Q54115801-F80A21D6-77A8-41F4-8039-8E00C089E08B
P2860
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
(S)-1-[3-hydroxy-2-(phosphonyl ...... antiviral nucleotide analogue.
@en
type
label
(S)-1-[3-hydroxy-2-(phosphonyl ...... antiviral nucleotide analogue.
@en
prefLabel
(S)-1-[3-hydroxy-2-(phosphonyl ...... antiviral nucleotide analogue.
@en
P2093
P356
P1476
(S)-1-[3-hydroxy-2-(phosphonyl ...... antiviral nucleotide analogue.
@en
P2093
J C Martin
J Flaherty
J Hannigan
J P Lalezari
P E Fisher
P304
P356
10.1093/INFDIS/171.4.788
P407
P577
1995-04-01T00:00:00Z